The objective of this study was to characterize the heparin-binding properties of a protein secreted by mouse myeloma cells. The characterization was performed using clinical assays, such as heparin activity assays and heparin-induced thrombocytopenia (HIT) platelet activation assays. The tests were performed in the presence of heparin, lowmolecular-weight heparins (LMWH), or heparinoids and either heparin-binding protein (HBP) or saline to determine whether the HBP affects the activity of heparins. The characterization of the HBP using heparin activity assays showed that the HBP shortened the prolonged clotting times of the activated partial thromboplastin time (aPTT) and thrombin clotting time induced by high concentrations of unfractionated heparin. The chromogenic assays for antithrombin (AT), thrombin inhibition, and factor Xa inhibition demonstrated that this effect is related to heparin concentrations below 0.5 IU/ml. The Heptest assay did not detect these differences. The HBP did not modify the anticoagulant effect of any LMWH or low-or high-sulfated glycosaminoglycans in the aPTT assay. Activation of donor platelets in the presence of unfractionated heparin, platelet factor 4 (PF4), and HIT-serum was not counteracted by the HBP in any of the assays. The characterization of the HBP using a PF4-enzyme-linked immunosorbent assay (ELISA) confirmed the lack of structural identity with PF4. However, the optical density data indicated that the protein structure may be similar to PF4 by binding to a PF4 antibody. These data suggest that the HBP isolated from mouse myeloma cells has a low affinity to heparin and interacts with the secondary binding site to AT and also perhaps to PF4.
The high biocompatibility and low antigenic potency of heparins is reflected by the lack of heparin antibodies despite their widespread occurrence in tissues and during heparinization of patients. Consequently, only a few reports exist on the detection of antiheparin activity in patients with dysproteinemia and malignant disease. Therefore, only a few reports on the successful production of monoclonal antibodies against heparins and other glycosaminoglycans have been published.
Antibodies have been raised against heparan sulfate, 1,2 chondroitin sulfate, 3 and keratin sulfate. 4, 5 The production of heparin antibodies has been reported. [6] [7] [8] [9] However, further analysis has shown that the antibodies were not directed against native heparin but against heparin conjugates or chemically modified heparins. The reason for the low antigenicity of glycosaminoglycans may be suggested by the nonprotein structure of these compounds.
Pejler et al 6 reported on monoclonal antibodies specific for oligosaccharides prepared by partial nitrous acid deamination of heparin. The resulting antibody did not recognize intact heparin but did recognize heparin fragments containing the anhydromannitol residue. Gitel et al 7 described polyclonal heparin antibodies produced in rabbits that recognized only heparin covalently adsorbed to a methylated polymer of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and did not react with free heparin. Strauss et al 8 reported on a monoclonal antibody of the immunoglobulin M (IgM) class. The antibody was directed against heparin but showed increased sensitivity when heparin was linked noncovalently to surfaces precoated with polylysine compared with free heparin in solution.
A monoclonal HBP secreted by mouse myeloma cells has been characterised by Huhle et al. 9 This HBP detected unfractionated heparin and LMWH, in contrast to the antibodies described to date in the literature that detect only modified or surface-attached heparin molecules. The smallest disaccharide unit able to bind to the HBP was the iduronic acid-anhydromannitol. The end point attachment of tyramine to the anhydromannose did not influence the HBP binding, indicating the importance of the iduronic acid for binding of glycosaminoglycans to the HBP.
Formerly, the HBP was referred to as the first monoclonal antibody to heparin. Analyses and applications of the HBP by ELISA methods demonstrated that this compound was not a native antibody and that it could not be detected by any anti-immunoglobulin antibody routinely used for antibody purification. In addition, other routinely used antibody purification techniques failed concerning this substance. Further investigations showed that the compound binding to heparin is not secreted by the hybridoma cell line H1.18, as assumed earlier, but by the mouse myeloma cell line Ag8.
In this article, we describe the anticoagulant and platelet activation data of the HBP. The characterization was performed using clinical assays, such as heparin activity assays and HIT platelet activation assays.
MATERIALS AND METHODS

Isolation of the HBP
The mouse myeloma cell line Ag8, kindly supplied by Prof. W. W. Franke, German Cancer Research Center, Heidelberg, was cultivated in RPMI 1640 medium (Sigma, St. Louis, Missouri) in polystyrene tissue flasks. Each second day, cell culture supernatant was harvested, centrifuged at 250g for 10 minutes, clarified from cell detritus and particles by filtration through microfilters with a 0.2-µm pore size, and stored in aliquots at Ϫ80°C.
Ammonium sulfate precipitation of the HBP was performed at 4°C. Myeloma cell culture supernatant was brought to a final concentration of 70% ammonium sulfate by adding saturated ammonium sulfate solution. After 12 hours' incubation, the material was centrifuged at 15,000g for 20 minutes. The precipitate was redissolved and dialyzed against 0.9% NaCl using a membrane with a cutoff of 100 kD. The precipitation was repeated at 8% ammonium sulfate concentration. The pellet was discarded, and the supernatant was brought to a concentration of 32% ammonium sulfate. The pellet of this precipitation step was redissolved, and the salt was removed by dialysis.
The protein content of the HBP was measured by the Bradford method. 10 Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) was performed as described by Laemmli. 11 Gels were stained with silver nitrate as described by Switzer et al 12 and photographed for documentation. The SDS-PAGE demonstrated the purification yield of the HBP. Albumin was effectively eliminated.
Characterization of HBP Using Heparin Activity Assays
All tests were performed using the HBP, partially purified and albumin free, at a protein concentration of 1 mg/mL. The HBP was coupled with unfractionated heparin (Elkins Sinn, Cherry Hill, New Jersey). These complexes were prepared by diluting heparin 1:10 in HBP to obtain final concentrations of 10, 5, 2.5, 1.25 IU/mL heparin to HBP and were incubated overnight. Test plasma was prepared by diluting the coupled HBP 1:10 in pooled normal human plasma (n = 6 donors).
HEPTEST
The Heptest® (Haemachem, St. Louis, Missouri) assay measures factor Xa and to some extent factor IIa inhibition. Purified bovine factor Xa and test plasma (HBP coupled to heparin and supplemented to human plasma) were incubated for 2 minutes at 37°C. Clotting time was determined on a Fibrometer® (BBL, Cock-eysville, Maryland) after the addition of 100 L of prewarmed Recalmix. Clotting times beyond 300 seconds were outside the linear range of the instrument.
THROMBIN CLOTTING TIME
The 5-unit thrombin clotting time (TCT) measures the time it takes to convert fibrinogen to fibrin by preformed thrombin. Two hundred microliters of test plasma were equilibrated to 37°C for 3 minutes. The clotting time was measured using a Fibrometer after addition of 100 L prewarmed Fibrindex® human thrombin (Ortho Diagnostics, Raritan, New Jersey). Clotting times beyond 300 seconds were outside the linear range of the instrument.
ACTIVATED PARTIAL THROMBOPLASTIN TIME
The aPTT is a global clotting assay that measures the activity of the coagulation factors in the intrinsic pathway and is commonly used to monitor heparin therapy. One hundred microliters of aPTT reagent (Organon Teknika, Durham, North Carolina) were added to 100 L of plasma and incubated for 5 minutes at 37°C. Clotting time was measured using a Fibrometer after the addition of 100 L prewarmed 0.025 M calcium chloride. Clotting times beyond 300 seconds were outside the linear range of the instrument.
ANTITHROMBIN ASSAY
The ability of an agent to mediate antiprotease activity via AT was measured using an amidolytic substrate assay run on the ACL-300+ kinetic analyzer (Instrumentation Laboratory [IL], Lexington, Massachusetts). Test plasmas were diluted 1:10 in saline and placed in sample cups. The first reagent consisted of 1.25 IU/ml thrombin in Tris buffer (50 mM Tris, 175 mM NaCl, 7.5 mM EDTA, pH = 8.4 at 25°C). The final concentration of thrombin was 0.0625 IU/mL. The second reagent was 0.5 nM Spectrozyme TH (American Diagnostica, Greenwich, Connecticut). The instrument was programmed such that 100 L of plasma and 100 L of reagent 1 were placed into individual compartments in a reaction rotor. These reagents were incubated at 37°C for 1 minute before being mixed together. Then, 50 L of reagent 2 were added to the reaction rotor, which was spun at 1200 rpm to mix all reagents. Optical density readings at 405 nm for all reactions were made for 60 seconds.
ANTI-FACTOR XA ASSAY
Inhibition of factor Xa was measured using an amidolytic assay run on the ACL-300. Anticoagulant present in plasma inhibits factor Xa. Residual factor Xa cleaves a chromogenic substrate to release paranitroaniline (pNA). The reaction is monitored by measuring the change in the amount of free chromophore pNA detected by the change in optical density at 405 nm. Three hundred seventy-five microliters of buffer (50 nm Tris, 175 nM NaCl, 7.5 nM ethylenediaminetetraacetic acid [EDTA], pH = 8.4 at 25°C) were incubated with 25 L of test plasma for 2 minutes at 37°C. The instrument was programmed such that 50 L of Spectrozyme FXa (2.5 nM) (American Diagnostica) were added, and the change in optical density at 405 nm was measured for 1 minute.
ANTI-FACTOR IIA ASSAY
Inhibition of factor IIa was measured using an amidolytic assay run on the ACL-300. Anticoagulant present in plasma inhibits factor IIa. Residual factor IIa cleaves a chromogenic substrate to release pNA. The reaction is monitored by measuring the change in the amount of free chromophore pNA detected by the change in optical density at 405 nm. Four hundred microliters of buffer (50 nm Tris, 175 nM NaCl, 7.5 nM EDTA, pH = 8.4 at 25°C) and 25 L of plasma were prewarmed for 1 minute at 37°C. then 25 L of 10 IU/ml thrombin (Ortho) were added. After a 1-minute incubation, 50 L of 1-mM Spectrozyme TH (American Diagnostica) were added, and the change in optical density at 405 nm was measured for 1 minute.
APTT FOR ANALYSIS OF DIFFERENT ANTICOAGULANTS WITH HPB
The aPTT reagent was used as described previously to test the following substances for binding to the HBP. This reagent was chosen because it had shown a relevant effect of HBP on heparin activity (see later) and because at adequate high concentrations of the compounds mentioned later, an interaction with the HBP was assumed. The LMWHs ardeparin (Wyeth, Cincinnati, Ohio), dalteparin (Pharmacia, Kalamazoo, Michigan), enoxaparin (Rhone-Poulenc Rorer, Bridgewater, New Jersey), and nadroparin (Sanofi-Synthelabo, Paris, France); the polysulfated aprosulate (Luitpold, Munich, Germany); a hypersulfated LMWH (Recordati, Milan, Italy); and the heparinoids ateroid (Crinos, Milan, Italy) and danaparoid (Organon, Oss, The Netherlands) were tested. The substances were used in final concentrations equivalent to the activity of heparin at 1.0, 0.5, 0.25, 0.125, and 0 IU/mL. They were diluted in either saline or 1 mg/mL HBP. The complexes were incubated overnight. The time to clot of the aPTT by the agents incubated with HBP or saline was compared.
Characterization of the HBP Using HIT Platelet Activation Assays
Blood from healthy individuals was drawn using a double-syringe technique. The assays were performed with serum from patients diagnosed with HIT as the source of antiheparin and PF4 antibodies. These antibodies form complexes with heparin and activate platelets. Heparin was diluted in saline or 1 mg/mL HBP.
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FLOW CYTOMETRY ASSAY
One hundred sixty microliters HIT serum; 50 L heparin in saline or HBP at concentrations of 0, 1, 5, and 1000 IU/mL; and 290 L nonanticoagulated whole blood were incubated for 10 minutes at 37°C, with stirring. Immediately after blood collection, 50 L of whole blood were fixed in 1 mL of fixing solution (Sigma) for the nonactivated control. The fixing solution consisted of 2% paraformaldehyde diluted 1:2 in Tyrode's buffer. For each test, 50 L of whole blood was fixed after a 10-minute reaction time. After a 30-minute fixation time at 4°C, the samples were centrifuged at 320g for 10 minutes. The supernatant was removed carefully to avoid disturbing the cells. After the addition of 400 L Tyrode's buffer, 100 L of the diluted cells were placed into test tubes containing 100 L each of CD61-FITC and CD62-PE antibodies (Becton Dickinson, San Jose, California) diluted 1:30 in Tyrode's buffer. The samples were incubated for 30 minutes at room temperature in the dark and then diluted with 400 L Tyrode's buffer and analyzed in the flow cytometer (Becton Dickinson). Parameters for platelet activation, platelet aggregation, and expression of P-selectin of the total platelets were tabulated in percent.
AGGREGOMETRY
To obtain platelet-rich plasma (PRP), 30 ml citrated whole blood was collected and centrifuged at 160g for 15 minutes. The PRP was removed. The remaining blood was centrifuged at 600g for 10 minutes to obtain platelet-poor plasma (PPP). To calibrate the aggregometer baseline, 500 L of PPP were placed in a cuvette. Three hundred microliters of HIT serum or normal serum (NHS) and 200 L of PRP were incubated for 3 minutes at 37°C. Fifty microliters of 0, 1, 5, and 100 IU/ml heparin in saline or HBP were added, and the aggregation response recorded for 20 minutes.
C-SEROTONIN RELEASE ASSAY
The serotonin release assay (SRA) tests for the presence of HIT antibodies by incubating patient serum and heparin with radiolabeled donor platelets. Platelet activation caused by the antiheparin-PF4 antibody was measured by quantitating 14 C-serotonin released from the platelets. Radiolabeling of platelets was performed as follows. Acid-citrate-dextrose (ACD) anticoagulated blood was centrifuged at 160g for 15 minutes to obtain PRP; the ACD-PRP was incubated with 0.1 Ci/ml 14 C-serotonin for 40 minutes and then centrifuged at 400g for 10 minutes. The supernatant was discarded, and the sediment with the platelets was washed in 10 ml of calcium and albumin-free Tyrode's (AFT) buffer containing 0.15 mg of apyrase. The platelet count was adjusted to 300 ± 50 ‫ן‬ 10 9 /L. The assay was performed in the following manner: 30 L of AFT buffer and 70 L of labeled platelets were placed in the appropriate microtiter well as the background sample. Previously tested HIT-positive serum was run as a positive control. Added to the appropriate microtiter well were 10 L of 0, 1, and 1000 IU/ml heparin in saline or in HBP; 20 L of the positive control; and 70 L of the labeled platelets. Final heparin concentrations were 1:10 of the preceding concentrations. The microtiter plate was covered and placed on a shaker at 120g for 60 minutes at room temperature. To stop the reaction, 100 L of 4.0% EDTA were added. The contents of each well were transferred to a plastic vial and centrifuged at 1500g for 2.5 minutes to pellet the platelets. The supernatant radioactivity was measured by adding 100 L of the supernatant to 5 ml of scintillation fluid. The radioactivity was counted for 3 minutes.
PF4-ELISA
An Asserachrom® PF4 kit (Diagnostica Stago, Paris, France) was used to quantify PF4 in test material. Two hundred microliters standard solutions of PF4 were prepared for a calibration curve and incubated in microtiter plates coated with rabbit antihuman PF4 antibody. Then, 200 L of 1.0, 0.5, and 0.25 mg/ml HBP were placed into the appropriate wells. Five percent human albumin was run as negative control. The provided dilution buffer set the background. After a 60-minute incubation, the plate was washed five times with the washing buffer provided using an automated plate washer. Next, 200 L of rabbit anti-PF4 antibody coupled with peroxidase was added and allowed to incubate for 60 minutes. After washing five times with buffer, 200 L of the substrate ortho-phenylenediamine (OPD), activated with hydrogen peroxide, were added and incubated for 3 minutes. The enzyme reaction was stopped with 50 L of 3M sulfuric acid, and the absorption was read at 492 nm within 10 minutes.
RESULTS
Inhibition of factors Xa and
IIa by AT is accelerated by heparin. The amount of factor Xa or factor IIa activity neutralized during a specific time is directly proportional to the concentration of heparin in the reaction mixture. Heparin was diluted 1:10 in normal human plasma for a calibration curve, the final concentrations were 1.0, 0.5, 0.25, 0.125, and 0 IU/mL. The Heptest assay determines mainly factor Xa inhibition and to some extent factor IIa inhibition. The heparin concentration detected in the test plasma, which consisted of HBP-heparin complexes, was similar to the heparin concentration detected without HBP in the Heptest assay (Fig. 1) . Therefore, the HBP did not affect the factor Xa and factor IIa inhibiting activity of heparin in this assay.
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The TCT is prolonged in the presence of heparin because of the inhibition of factor IIa by the heparin-AT complex. The HBP substantially shortened the prolongation of the coagulation times caused by heparin. This indicates binding of long saccharide chains of the heparin molecule by the HBP (Fig. 2) . The longer saccharide units of heparin are responsible for the inhibition of thrombin. This agrees with the finding in the Heptest assay, which is prolonged mainly by LMWH and thus is more sensitive toward factor Xa than it is to factor IIa inhibition.
The HBP affected the prolongation of the aPTT by heparin in a similar pattern, as observed in the timed TCT (Fig. 3) . The shortening of the aPTT by HBPheparin complexes compared with that of heparin alone may be somewhat less pronounced compared with the thrombin inhibition assay because aPTT is sensitive to both longer and shorter heparin chains. Therefore, the aPTT assay was chosen for the interaction studies of the HBP and the other glycosaminoglycans.
The chromogenic AT, anti-factor Xa, and antifactor IIa assays measured the interaction between heparin and the HBP in more detail. At concentrations below 0.5 IU/ml, the AT-mediated antiprotease activity of heparin was inhibited from 30 to 50% by the HBP. However, the results were similar at 1 IU/mL heparin in the presence of either saline or HBP (Figs. 4 to 6 ). These results indicate that the HBP is not capable of affecting the heparin activity on thrombin and factor Xa if the concentration of heparin is more than 0.5 IU/mL in these assays.
The aPTT reagent was chosen to analyze the interaction of the HBP with the different glycosaminoglycans. Some of the available LMWH compounds, as well as the low-sulfated (danaparoid) and over-sulfated compounds, were studied. The concentrations of the compounds were high to substantially prolong the aPTT in the presence of saline. After incubation with 1 mg/ml HBP, no dose dependent inhibition of the activity in the assay was observed. The single difference found was less than 30% of inhibition, and it occurred at EFFECTS OF HEPARIN-BINDING PROTEIN/KAISER ET AL.
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__ ls __ le __ ll only one and not at the same concentration of the compounds. The activity of the LMWHs did not differ in the presence of saline and HBP up to 1 IU/mL. The degree of sulfation did not seem to play a major role in the interaction with HBP in this assay. Therefore, the HBP did not affect the aPTT, factor IIa, and factor Xa inhibiting activity of any glycosaminoglycans other than unfractionated heparin.
The flow cytometry was performed with HIT serum and showed a platelet aggregation of 7.4% without heparin and 4.5, 3.2, and 7.9% in the presence of 0.1, 0.5, and 100 IU/ml heparin in saline, respectively. The expression of P-selectin was 25.3, 39.4, and 16.1% in the presence of the different heparin concentrations in saline, respectively. In the presence of HBP, heparin caused platelet aggregation of 9, 2.4, and 8.3% and P-selectin expression of 12.2, 35.9, and 11.1%, respectively. These data demonstrate that at less than 0.5 IU/mL, heparin expression of P-selectin is counteracted by HBP in the presence of HIT serum, heparin, and donor platelets using flow cytometry analysis. This agrees with the results obtained in the blood coagulation studies.
Platelet aggregometry was performed using two different HIT sera (A and B) to activate platelets. Normal human serum, run as negative control led to no activation of the platelets, and HIT serum A caused a 20% activation without adding heparin. After the addition of heparin diluted in saline in the concentrations of 1, 5, and 100 IU/ml, the final platelet activation was 88, 86, and 86%, respectively. The time to 50% of final activation was 0, 140, 125, and 310 seconds for 0, 1, 5, and 100 IU/ml. HIT serum B caused an activation of 13% without heparin; 1, 5, and 100 IU/ml heparin in saline activated platelets to 75, 70, and 16%, respectively. The time to 50% of the final activation was 0, 105, 190, and 0 seconds for the respective concentrations of heparins.
The HBP had the following effects on heparin in the presence of HIT serum and donor platelets in the 500 SEMINARS IN THROMBOSIS AND HEMOSTASIS/VOLUME 27, NUMBER 5 2001 ls __ le __ ll __ Figure 4 The concentration of heparin (IU/mL) is plotted against the OD at 405 nm in the presence of saline (control, open symbols) and 1 mg/ml HBP (closed symbols) using the AT assay.
Figure 5
The concentration of heparin (IU/ml) is plotted against the OD at 405 nm in the presence of saline (control, open symbols) and 1 mg/ml HBP (closed symbols) using the chromogenic anti-IIa assay.
Figure 6
The concentration of heparin (IU/ml) is plotted against the OD at 405 nm in the presence of saline (control, open symbols) and 1 mg/ml HBP (closed symbols) using the chromogenic anti-Xa assay.
and HIT serum was not counteracted by the HBP in any of the platelet assays. It is assumed that PF4 possesses a higher affinity to heparin than the HBP does. For binding of AT to heparin, a high-affinity binding site, that is, the pentasaccharide binding site, and a lesscharacterized secondary binding site have been defined. The characterization of the HBP using a PF4-ELISA confirms the suggestion of a lack of structural identity with PF4. However, the OD data indicate that the protein structure may be similar to PF4 by binding to a PF4 antibody. We also suggest that the HBP has a low affinity to heparin and interacts with the secondary binding site to AT.
